Intuit Inc. (NASDAQ: INTU) was reiterated as Overweight and its price target was raised to $285 from $275 (versus a $267.78 close) at KeyBanc Capital Markets.
Kura Oncology Inc. (NASDAQ: KURA) was started with an Overweight rating and a $24 price target (versus a $14.70 close) at Barclays.
L Brands Inc. (NYSE: LB) was raised to Outperform from Market Perform with a $17 price target (versus a $12.04 close) at BMO Capital Markets. It had a $16.21 consensus price target.
ONEOK Inc. (NYSE: OKE) was downgraded to Neutral from Outperform at Credit Suisse.
Owens & Minor Inc. (NYSE: OMI) was downgraded to Neutral from Outperform at Robert W. Baird
Peloton Interactive Inc. (NASDAQ: PTON) was reiterated as Buy and its price objective was raised to $41 from $36 (versus a $33.90 close) at BofA Securities. The consensus price target was $38.48.
Replimune Group Inc. (NASDAQ: REPL) was started with an Overweight rating and a $21 price target (versus a $15.93 close) at Barclays.
Salesforce.com Inc. (NYSE: CRM) was started with a Sell rating and a $120 price target at Rosenblatt. Shares closed up over 3% at $161.47 ahead of this call and had a $194.38 consensus price target. They were indicated up 0.2% on Tuesday.
Shake Shack Inc. (NYSE: SHAK) was reiterated as Hold but its price target was raised to $55 from $50 (versus a $52.77 close) at SunTrust Robinson Humphrey. Wedbush Securities reiterated its Neutral rating, along with a $50 price target.
TripAdvisor Inc. (NASDAQ: TRIP) was maintained with a Buy rating but its price target was lowered to $26 from $39 (versus an $18.72 close) at Needham.
Tyson Foods Inc. (NYSE: TSN) was down 7.8% at $55.32 after earnings on Monday. BofA Securities downgraded it to Neutral from Buy and cut its price objective to $60 from $70.
Wells Fargo & Co. (NYSE: WFC) was downgraded to Underweight from Neutral with a $25 price target at Atlantic Equities.
Workday Inc. (NASDAQ: WDAY) was started with a Sell rating and a $110 price target at Rosenblatt. The stock closed up 1.2% at$148.47 ahead of the call, with a $175.16 consensus price target.
Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) was started as Overweight with a $44 price target (versus a $33.80 close) at Barclays.
The BofA Securities analysts have a Yield Advantage group of stocks that are outperforming other high dividend shares. We selected five from the list with big dividends and a Buy rating.
Monday’s top analyst upgrades and downgrades included AON, Cognizant Technology Solutions, Dow, PayPal, PG&E, PNC Financial Services, Qualcomm, Shopify, Tesla, Valero Energy, Walt Disney, Wells Fargo and more.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.